Xeris Biopharma Holdings (XERS) Change in Account Payables (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Change in Account Payables of $4.2 million for Q1 2026, up 350.29% on a QoQ basis from -$1.7 million in Q4 2025, and up 4.63% year-over-year from $4.1 million in Q1 2025.
Xeris Biopharma Holdings (XERS) Change in Account Payables (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Change in Account Payables history runs 7 years deep, the most recent figure standing at $4.2 million for Q1 2026.
- Quarterly Change in Account Payables rose 4.63% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119000.0 (up 111.02% YoY) and the FY2025 annual result came in at -$69000.0, up 99.28% from the prior year.
- Change in Account Payables was $4.2 million for Q1 2026 at Xeris Biopharma Holdings, up from -$1.7 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $6.9 million in Q1 2023 and bottomed at -$5.2 million in Q4 2024.
- A 5-year average of -$164176.5 and a median of $80000.0 in 2023 frame the typical range for Change in Account Payables.
- Peak annual rise in Change in Account Payables reached 456.57% in 2024, while the deepest fall reached 2090.0% in 2024.
- Xeris Biopharma Holdings' Change in Account Payables stood at $690000.0 in 2022, then slumped by 151.16% to -$353000.0 in 2023, then sank by 1373.94% to -$5.2 million in 2024, then surged by 67.36% to -$1.7 million in 2025, then jumped by 350.29% to $4.2 million in 2026.
- Business Quant data shows XERS's Change in Account Payables at $4.2 million in Q1 2026, -$1.7 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 4.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.25 Mn |
| Mar 31, 2026 | 4.25 Mn |
| Dec 31, 2025 | -1.70 Mn |
| Dec 31, 2025 | -1.70 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | -4.43 Mn |
| Jun 30, 2025 | -4.43 Mn |
| Mar 31, 2025 | 4.06 Mn |
| Mar 31, 2025 | 4.06 Mn |
| Dec 31, 2024 | -5.20 Mn |
| Dec 31, 2024 | -5.20 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | -1.59 Mn |
| Jun 30, 2024 | -1.59 Mn |
| Mar 31, 2024 | -4.47 Mn |
| Mar 31, 2024 | -4.47 Mn |
| Dec 31, 2023 | -353,000.00 |
| Dec 31, 2023 | -353,000.00 |